Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTC4S | Q16873 | 11/20 | 0.47 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.43 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.43 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.43 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.43 |
| ▸ | PNLIP | P16233 | 3/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL237289 | 0.91 | LTC4S (0.49) | LTC4SKCNQ3KCNQ2KCNE1KCNQ1 | |
| SCHEMBL239488 | 0.89 | KMT2A (0.43) | P2RX3MEN1KMT2AKCNQ3KCNQ2 | |
| SCHEMBL239894 | 0.87 | KMT2A (0.43) | LTC4SP2RX3MEN1KMT2AKCNQ3 | |
| SCHEMBL238403 | 0.85 | LTC4S (0.64) | LTC4S | |
| SCHEMBL238194 | 0.83 | LTC4S (0.47) | LTC4SP2RX3MEN1KMT2A | |
| SCHEMBL237749 | 0.82 | HSD17B10 (0.44) | LTC4S | |
| SCHEMBL240022 | 0.78 | LTC4S (0.49) | LTC4SMEN1KMT2A | |
| SCHEMBL27849459 | 0.78 | P2RX3 (0.45) | P2RX3MEN1KMT2AKCNQ3KCNQ2 | |
| SCHEMBL239013 | 0.76 | LTC4S (0.69) | LTC4S | |
| SCHEMBL240019 | 0.74 | LTC4S (0.46) | LTC4S |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120004244-A1 | Bis Aromatic Compounds for Use as LTC4 Synthase Inhibitors | BIOLIPOX AB (SW) | 2012-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120004244-A1 | Bis Aromatic Compounds for Use as LTC4 Synthase Inhibitors | LTC4S, LTB4R2, LTB4R | LTC4S 1/4885P2RX3 861/4885MEN1 4148/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.